GYRE THERAPEUTICS, INC. (GYRE) Financial Statements
GYRE THERAPEUTICS, INC. (GYRE) reported trailing twelve-month revenue of $119.4M (up 16.8% year on year) and net income of -$28.2M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: -$6.1M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
GYREGYRE THERAPEUTICS, INC.Follow GYRE — free
—
Price chart with a free account
- Market cap
- 652.3M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 18 Nov, in 24 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2011 Dec 11 | FY2012 Dec 12 | FY2013 Dec 13 | FY2014 Dec 14 | FY2018 Dec 18 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 97.6 | 57.9 | 3.6 | 0.3 | 0.0 | 20.9 | 7.3 | 102.3 | 113.5 | 105.8 | 116.6 | 119.4 | |
| Gross profit | — | — | — | — | — | — | — | — | 108.8 | 101.9 | 111.2 | — | |
| Research & development | 95.2 | 49.1 | 6.6 | 5.3 | 21.5 | 53.0 | 68.9 | 16.7 | 13.8 | 12.0 | 13.7 | — | |
| Operating income | -9.7 | -8.1 | -10.1 | -7.5 | -33.8 | -57.4 | -87.9 | 9.2 | -67.2 | 16.2 | 11.5 | -16.7 | |
| Pre-tax income | -8.5 | -7.1 | -46.7 | -29.1 | — | — | — | 9.4 | -77.0 | 23.2 | 14.4 | -16.1 | |
| Income tax | 0.0 | -0.1 | 0.0 | 3.5 | — | — | — | 5.1 | 8.5 | 5.3 | 4.6 | 3.5 | |
| Net income | -8.5 | -7.0 | -10.0 | -6.6 | -30.1 | -56.2 | -87.9 | 4.3 | -85.5 | 17.9 | 9.9 | -28.2 | |
| Diluted EPS ($) | -0.27 | -0.21 | -27.29 | -17.99 | -2.68 | -2.93 | -2.87 | 0.03 | -1.41 | 0.05 | 0.02 | -0.21 | |
| Diluted shares (mn) | 31.6 | 33.5 | — | — | — | — | 30.6 | 75.7 | 65.8 | 102.3 | 103.2 | — |
USD millions · SEC XBRL
GYRE THERAPEUTICS, INC. — questions
- What is GYRE THERAPEUTICS, INC.'s revenue?
- $119.4M over the twelve months to 2026-06-30, up 16.8% year on year, from its 10-Q and 10-K filings.
- What is GYRE THERAPEUTICS, INC.'s net income?
- -$28.2M over the twelve months to 2026-06-30.
- What is GYRE THERAPEUTICS, INC.'s free cash flow?
- -$6.1M over the twelve months to 2026-06-30.
- What are GYRE THERAPEUTICS, INC.'s diluted earnings per share?
- $-0.21 over the twelve months to 2026-06-30.
Every figure on this page comes from GYRE THERAPEUTICS, INC.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.